Alcon Q3 2026: Margin Expansion Powers an Earnings Beat Despite Light Revenue

Alcon reported adjusted earnings of $0.91 per share in its third quarter of fiscal 2026, clearing the consensus estimate of $0.89 by about 2.25%. Revenue came in at $2.74 billion, fractionally below the $2.74 billion estimate, a miss of just 0.16%, while still growing 4.7% from the year-ago period.

The clearest story of the quarter was what happened below the top line. Gross margin expanded to 59.7% from 56.3% a year earlier, and core operating margin rose to 21.8% from 20.2%. Part of that improvement came from a one-time source: $58 million in tariff refunds following a U.S. Supreme Court ruling against IEEPA tariffs. Manufacturing efficiencies and lower amortization charges also contributed.

By segment, Vision Care outpaced the rest of the business with 6% growth, led by premium contact lens mix, ocular health products including Tryptyr and Systane, and an 8% gain in the ocular health line. Surgical grew 4%, though Implantables slipped 2% under competitive pressure in the U.S. intraocular lens market. Equipment and other products grew 11%, helped by launches including the UNITY M premium ophthalmic microscope.

Looking at the broader EPS trend, Alcon has now reported at or above consensus in most recent quarters, with adjusted EPS climbing from $0.72 in Q4 2024 to $0.91 this quarter. The trajectory reflects both top-line progress and steady margin improvement, though the tariff refund in Q3 was a meaningful non-recurring tailwind that investors will want to strip out when assessing the underlying run rate.

Management tightened full-year 2026 guidance to approximately 6% constant-currency sales growth and core diluted EPS growth of 12% to 14%, narrowing ranges that had previously been wider on both ends. The company also noted a full-year net tariff impact of about $40 million, which accounts for the roughly $60 million U.S. refund offset against ongoing U.S. import tariff rates of 10% to 12.5%. Whether the margin expansion can hold without a repeat of that refund is the central question heading into the fourth quarter.

On the capital return front, Alcon repurchased $210 million of shares in Q3 under a $1.5 billion buyback program authorized in May 2026, with approximately $1.0 billion remaining as of September 30, 2026. The company also completed the acquisition of Neurotech Pharmaceuticals for $550 million at closing, adding the ENCELTO retinal therapy to its portfolio and signaling continued appetite for pipeline expansion alongside the organic efficiency push.